SBR759A + SBR759A + SBR759A + SBR759A + SBR759A
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Trial Timeline
Feb 1, 2010 → —
NCT ID
NCT01069692About SBR759A + SBR759A + SBR759A + SBR759A + SBR759A
SBR759A + SBR759A + SBR759A + SBR759A + SBR759A is a phase 3 stage product being developed by Novartis for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01069692. Target conditions include Hyperphosphatemia, Chronic Kidney Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01069692 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperphosphatemia